Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lecanemab reduces brain amyloid-β and delays cognitive worsening
David S. Knopman
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100982-100982
Open Access | Times Cited: 16

Showing 16 citing articles:

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
Selia Chowdhury, Nurjahan Shipa Chowdhury
International Journal of Immunopathology and Pharmacology (2023) Vol. 37
Open Access | Times Cited: 31
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
Rawan Tarawneh, V. Shane Pankratz
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 13
The complement system in neurodegenerative diseases
Jacqui Nimmo, Robert A. J. Byrne, Nikoleta Daskoulidou, et al.
Clinical Science (2024) Vol. 138, Iss. 6, pp. 387-412
Open Access | Times Cited: 7
Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going?
Ni Liu, Anaer Haziyihan, Wei Zhao, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center
Lisa B.E. Shields, H Hust, Susan Cooley, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
β-Amyloid Induces Microglial Expression of GPC4 and APOE Leading to Increased Neuronal Tau Pathology and Toxicity
Brandon B. Holmes, Thaddeus K. Weigel, Jon Chung, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence
Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka, et al.
Journal of Alzheimer s Disease (2025)
Closed Access
Fyn-ding Novel Therapeutic Targets for Temporal Lobe Epilepsy—Unlikely Partners at the Hippocampal Synapse
Larissa Robinson‐Cooper, Melissa Barker‐Haliski
Epiliepsy currents/Epilepsy currents (2025)
Open Access
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model
Sarah Vanherle, A.J.M. Janssen, Manuel Gutiérrez de Ravé, et al.
Molecular Psychiatry (2025)
Open Access
PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use
Freimut D. Juengling, Frank Wuest, Ralf Schirrmacher, et al.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-13
Open Access | Times Cited: 2
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Jenny Garmendia, Claudia Valentina De Sanctis, Viswanath Das, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 6, pp. 1080-1109
Open Access | Times Cited: 6
Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease
Sohui Park, Jisu Shin, Kyeonghwan Kim, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 9, pp. 2650-2661
Open Access | Times Cited: 1
Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Madeline M. Vroom, Jean‐Cosme Dodart
Vaccines (2024) Vol. 12, Iss. 9, pp. 973-973
Open Access | Times Cited: 1
Cancer drugs with high repositioning potential for Alzheimer’s disease
Jad Majeed, Marwan N. Sabbagh, Min H. Kang, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 311-332
Closed Access | Times Cited: 2
A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease
Chanchal Sharma, Avijit Mazumder
Central Nervous System Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 1, pp. 45-56
Closed Access
Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab
Emre Fertan, Jeff Y. L. Lam, Giulia Albertini, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy
Massimiliano Germani, I. Rebollo Mesa, Tim Buchanan, et al.
Movement Disorders (2024)
Open Access
Is the NHS ready for new Alzheimer's disease treatments?
Mark Greener
Prescriber (2023) Vol. 34, Iss. 7, pp. 15-18
Open Access
Page 1

Scroll to top